Cell line · CVCL_1626
Papers35
1 to 20 of 35
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Structure-based redesign enables clinical translation of CAIX-targeted theranostics in clear cell renal cell carcinoma. | Theranostics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ALYREF-mediated m5C modification of CCNA1 drives escape from cell-cycle arrest and contributes to pazopanib resistance in Renal Cell Carcinoma. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP10 regulates HIF2α stability by deubiquitinating HIF2α regardless of VHL status in kidney cancer. | Transl Androl Urol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. | Commun Med (Lond) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC. | NPJ Digit Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fe-S Protein FDX1 Triggers Tumor-Intrinsic Innate Immunity via Mitochondrial Nucleic Acids Release to Orchestrate Ferroptosis in CCRCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERβ/circAHNAK Axis Inhibits USP10-FMR1 Deubiquitination to Prevent m⁶A-Mediated ADAM17 Decay and Promote Angiogenesis in Clear Cell Renal Cell Carcinoma. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ACE Loss Drives Renal Cell Carcinoma Growth and Invasion by Modulating AKT-FOXO1. | Biologics | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop. | J Exp Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A1CF Binding to the p65 Interaction Site on NKRF Decreased IFN-β Expression and p65 Phosphorylation (Ser536) in Renal Carcinoma Cells. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Fatty Acid Oxidation Mediated by Malonyl-CoA Decarboxylase Represses Renal Cell Carcinoma Progression. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination. | Exp Mol Med | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1626/papers